IN2014CN01466A - - Google Patents

Info

Publication number
IN2014CN01466A
IN2014CN01466A IN1466CHN2014A IN2014CN01466A IN 2014CN01466 A IN2014CN01466 A IN 2014CN01466A IN 1466CHN2014 A IN1466CHN2014 A IN 1466CHN2014A IN 2014CN01466 A IN2014CN01466 A IN 2014CN01466A
Authority
IN
India
Prior art keywords
amino acids
seq
linear
acid sequence
group
Prior art date
Application number
Other languages
English (en)
Inventor
Yoshimasa Sakamoto
Miyuki Nishimura
Tetsu Kawano
Yukihisa Sawa
Toshio Imai
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of IN2014CN01466A publication Critical patent/IN2014CN01466A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN1466CHN2014 2011-09-01 2012-08-30 IN2014CN01466A (xx)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161530194P 2011-09-01 2011-09-01
US201261659637P 2012-06-14 2012-06-14
PCT/JP2012/072667 WO2013032032A1 (en) 2011-09-01 2012-08-30 Anti-human xcr1 antibodies

Publications (1)

Publication Number Publication Date
IN2014CN01466A true IN2014CN01466A (xx) 2015-05-08

Family

ID=46881120

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1466CHN2014 IN2014CN01466A (xx) 2011-09-01 2012-08-30

Country Status (18)

Country Link
US (1) US9371389B2 (xx)
EP (1) EP2751140B1 (xx)
JP (1) JP5989096B2 (xx)
KR (1) KR101767717B1 (xx)
CN (1) CN103764680B (xx)
AR (1) AR087749A1 (xx)
AU (1) AU2012302596B2 (xx)
BR (1) BR112014004352A2 (xx)
CA (1) CA2846370C (xx)
ES (1) ES2684173T3 (xx)
HK (1) HK1199038A1 (xx)
IL (1) IL231075A (xx)
IN (1) IN2014CN01466A (xx)
MX (1) MX346560B (xx)
MY (1) MY166152A (xx)
RU (1) RU2619180C2 (xx)
TW (1) TWI563004B (xx)
WO (1) WO2013032032A1 (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101641206B1 (ko) * 2013-06-24 2016-07-22 에이비엘바이오 주식회사 안정성이 개선된 항체-약물 결합체 및 이의 용도
HUE059655T2 (hu) * 2015-08-05 2022-12-28 Acticor Biotech Új anti-humán GPVI antitestek és felhasználásuk
US11692033B2 (en) 2017-02-03 2023-07-04 Acticor Biotech Inhibition of platelet aggregation using anti-human GPVI antibodies
CA3050601A1 (en) 2017-02-07 2018-08-16 Vib Vzm Immune-cell targeted bispecific chimeric proteins and uses thereof
CN107312092B (zh) * 2017-05-04 2020-12-11 华南农业大学 一种斜带石斑鱼ccr12的多克隆抗体制备方法及其应用
WO2019068099A1 (en) * 2017-09-29 2019-04-04 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR MODULATION OF LYMPHOCYTE ACTIVITY SUPPRESSION
US20200354424A1 (en) * 2018-01-26 2020-11-12 Orionis Biosciences, Inc. Xcr1 binding agents and uses thereof
JP2022515473A (ja) 2018-12-28 2022-02-18 エフ．ホフマン－ラ ロシュ アーゲー 免疫応答が増幅された患者における治療的使用のためのペプチド－ｍｈｃ－ｉ－抗体融合タンパク質

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5786210A (en) 1994-02-08 1998-07-28 Schering Corporation Mammalian thymokine genes
JP2003530325A (ja) * 2000-03-31 2003-10-14 イーペーエフ ファルマシューティカルス ゲゼルシャフト ミット ベシュレンクテル ハフツング 好ましくは特異的ケモカインレセプター分析、及びケモカインレセプター／リガンド相互作用の助けによる、腫瘍及び炎症細胞の細胞表面プロテオームの調査、並びに腫瘍疾患及び炎症性疾患の治療のための診断薬及び薬剤
AU2002246557A1 (en) * 2000-11-29 2002-08-06 Lifespan Biosciences, Inc. Compositions and methods related to chemokine (c motif) xc receptor 1 (ccxcr1)
US20050136033A9 (en) 2002-08-13 2005-06-23 Matthias Mack Method of treating allergen induced airway disease
WO2004072646A1 (en) * 2003-02-13 2004-08-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 5 (gpr5)
EP1698902A1 (en) * 2005-03-01 2006-09-06 DKFZ Deutsches Krebsforschungszentrum Use of XCR1 for diagnosing or monitoring of immune tolerance
CN101293924A (zh) * 2007-04-24 2008-10-29 上海国健生物技术研究院 骨桥蛋白的功能表位、与其特异性结合的单克隆抗体及其在制备抗肿瘤转移药物中的用途
EP2062592A1 (en) 2007-11-20 2009-05-27 BUNDESREPUBLIK DEUTSCHLAND letztvertreten durch das Robert Koch-Institut vertreten durch seinen Präsidenten System for delivery into a XCR1 positive cell and uses thereof
BRPI1008441A2 (pt) * 2009-02-16 2016-10-11 Biolex Therapeutics Inc anticorpo humanizado, composição farmacêutica, método para tratar e prevenir um distúrbio de célula b em sujeito, composição de anticorpo anti-cd-20 humanizado, ácido nucléico isolado e célula hospedeira.

Also Published As

Publication number Publication date
AU2012302596A1 (en) 2014-03-06
JP5989096B2 (ja) 2016-09-07
RU2014106832A (ru) 2015-08-27
CN103764680A (zh) 2014-04-30
IL231075A0 (en) 2014-03-31
JP2014527396A (ja) 2014-10-16
TW201311725A (zh) 2013-03-16
ES2684173T3 (es) 2018-10-01
NZ621320A (en) 2015-11-27
IL231075A (en) 2017-08-31
EP2751140B1 (en) 2018-05-30
CN103764680B (zh) 2016-11-23
HK1199038A1 (en) 2015-06-19
BR112014004352A2 (pt) 2017-03-21
TWI563004B (en) 2016-12-21
CA2846370C (en) 2019-04-23
CA2846370A1 (en) 2013-03-07
US9371389B2 (en) 2016-06-21
RU2619180C2 (ru) 2017-05-12
AU2012302596B2 (en) 2016-12-01
MX346560B (es) 2017-03-24
EP2751140A1 (en) 2014-07-09
KR101767717B1 (ko) 2017-08-11
MX2014002078A (es) 2014-05-30
US20140193421A1 (en) 2014-07-10
MY166152A (en) 2018-06-06
WO2013032032A1 (en) 2013-03-07
KR20140054108A (ko) 2014-05-08
AR087749A1 (es) 2014-04-16

Similar Documents

Publication Publication Date Title
IN2014CN01466A (xx)
JOP20190017A1 (ar) أجسام مضادة ترتبط مع مستقبل cgrp بشري
NZ607969A (en) Cd33 binding agents
UA111818C2 (uk) Антитіло проти csf-1r
MA34524B1 (fr) Anticorps pour le récepteur 3 du facteur de croissance épidermique (her3)
NZ610267A (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
UA115402C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським
MX2019014658A (es) Anticuerpos humanizados que reconocen la alfa-sinucleina.
MX2016001356A (es) Proteina anti-garp y sus usos.
NZ713461A (en) Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)
MX2019000046A (es) Anticuerpos anti-il-23.
UA113609C2 (xx) Антигензв'язуючий білок, який зв'язує людський il-23
NZ601615A (en) Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
UA117901C2 (uk) Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
MX357193B (es) Moleculas de union anti-alfa sinucleina.
UA107574C2 (ru) Гуманизированное антитело, специфическое к протофибрилярной формы бета-амилоидного пептида
MY160590A (en) Cd127 binding proteins
MX2016004579A (es) Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas.
MX2012002565A (es) Purificacion de proteina mejorada a traves de una elucion de proteina a modificada.
MX2019015602A (es) Anticuerpos contra el beta-amiloide.
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
WO2012006341A3 (en) Anti-ron antibodies
NZ607720A (en) Peptide or peptide complex binding to 2 integrin and methods and uses involving the same
GB2496801A (en) A method of treating alzheimer's disease